Increased 6 months survival in breast malignant tumor patients brings a ray of hope
5 Oct 2012, USA (Buzzpharmacy.net): The new treatment with the drug named T-DM1, in the field of breast malignant tumors has brought a ray of hope for many. T-DM1 brings about survival length benefit of added 6 months, and while doing so it also helps in minimizing other negative effects. Apart from better quality life T-DM1also proved that it is effective in treating HER 2-positive advanced breast malignant tumor.
According to the ESMO data presented by Genentech mentioned that patient under T-DM1 treatment survived an average of 5.8 months, which is longer than other conventional treatment.
The data was also published in New England Journal of Medicine on 1st Oct 2012 which highlighted the good news of half year longer survival with T-DM1.
Javier Cortes from ‘Vall d'Hebron Institute of Oncology’ in Barcelona, Spain, stated at the Vienna meeting about never having seen increased length of survival rate before the development of new drug T-DM1.
Dietmar Berger, vice president of clinical oncology at Genentech, said that TDMI is further being studied to explore the beneficial results in elderly patient.
He further stated that, in older women, the growth of tumor is slow, and as such the detailed pattern is being further studied.
Cowen & Co. analyst Simos Simeonidis wrote in one of the research note that TDM-1 wins priority approvals and that it may be available in the market by the end of next February.
Tags: Breast Malignant Tumor , T-dm
This work is licensed under a Creative Commons Attribution 3.0 License.